This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Humana (HUM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of -57.14% and 1.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Ahead of Humana (HUM) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Humana (HUM) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Will the Individual MA Unit Aid Humana's (HUM) Q4 Earnings?
by Zacks Equity Research
Humana's (HUM) Q4 results are likely to gain from growing premiums and an expanding customer base within its individual Medicare Advantage and Medicaid units, partly offset by higher marketing spend.
Forget About a March Rate Cut: Focus on These 3 Stocks Poised to Rally
by Ethan Feller
Strong jobs data this morning shows just how strong the labor market is limiting the odds of rate cuts
Here's Why Humana (HUM) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Humana (HUM) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
Humana (HUM) closed at $459.30 in the latest trading session, marking a -0.31% move from the prior day.
Why Humana (HUM) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Cigna (CI) Nearing a Medicare Advantage Divestment Deal?
by Zacks Equity Research
Cigna's (CI) Medicare Advantage unit's divestment is expected to fetch around $3-$4 billion.
Humana (HUM) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
Humana (HUM) closed the most recent trading day at $464.52, moving -1.19% from the previous trading session.
Here's Why You Should Retain Humana (HUM) in Your Portfolio
by Zacks Equity Research
Humana (HUM) remains well-poised for growth, attributable to an aging U.S. population, contract wins, acquisitions and expanding cash reserves.
Humana (HUM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
The latest trading day saw Humana (HUM) settling at $455.61, representing a +0.93% change from its previous close.
Humana (HUM) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
The latest trading day saw Humana (HUM) settling at $453.94, representing a +0.45% change from its previous close.
The Zacks Analyst Blog Highlights UnitedHealth, Humana, Centene and Molina Healthcare
by Zacks Equity Research
UnitedHealth, Humana, Centene and Molina Healthcare are included in this Analyst Blog.
4 Health Insurers Likely to Maintain Winning Streak in 2024
by Debasmita Chatterjee
Medical-HMO stocks like UNH, HUM, CNC and MOH are expected to reap the benefits of an aging U.S. population and growing premiums in 2024. However, challenges related to the resumption of elective procedures might play spoilsport.
Here's Why Humana (HUM) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cigna's (CI) Medicare Advantage Unit Draws Acquisition Interest
by Zacks Equity Research
The final bids for Cigna's (CI) Medicare Advantage unit are expected next week.
Humana (HUM) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
Humana (HUM) concluded the recent trading session at $461.46, signifying a -1.62% move from its prior day's close.
Company News for Dec 12, 2023
by Zacks Equity Research
Companies In The News Are: M, CI, HUM, OXY, HAS.
Humana (HUM) Extends CINQCARE's Home Care Model to MA Members
by Zacks Equity Research
Humana (HUM) teams up with CINQCARE to offer better health outcomes for its Medicare Advantage members of New York.
Why Is Humana (HUM) Up 0.7% Since Last Earnings Report?
by Zacks Equity Research
Humana (HUM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Hold Humana (HUM) Stock for Now
by Zacks Equity Research
Humana (HUM) is expected to benefit from a strong growth outlook, upgraded health plan offering suite, expanding Medicare Advantage membership, and solid cash reserves.
Analyzing Cigna & Humana Merger Talks: Opportunities & Obstacles
by Kaibalya Pravo Dey
The Cigna-Humana merger will provide the combined body with increased negotiation power with healthcare providers, pharmaceutical companies and other stakeholders.
Time to Buy Cigna (CI) or Humana's (HUM) Stock on News of a Potential Merger?
by Shaun Pruitt
News of a potential mega-merger between Cigna (CI) and Humana (HUM) made headlines in today's trading session and investors may be wondering if now is a good time to buy stock in these health giants.
Why Humana (HUM) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Humana (HUM) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.